Press Releases

Eagle Pharmaceuticals, Inc., announced that AOP Orphan Pharmaceuticals GmbH, a member of the AOP Health Group, with whom Eagle entered into a licensing agreement in August 2021, submitted a new drug application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for landiolol, a short-acting, intravenous (“IV”), cardio-selective beta-1 adrenergic blocker. The submission seeks approval for landiolol for the short-term reduction of ventricular rate in pa

Lennham Pharmaceuticals, a start-up focused on the creative use of deuterium chemistry to improve the metabolic and pharmacological profile of existing compounds, today announced that the United States Patent & Trademark Office (USPTO) issued U.S. Patent No. 11,344,564 with an expiration date of December 2041. This patent covers methods of treating neurological or psychiatric disorders in patients having reduced monoamine oxidase A (MAO-A) activity by administering a below-normal dose of

Mezzion Pharma Co., Ltd. met with the FDA Division of Cardiology and Nephrology (DCN) on Friday, May 27th to discuss with the FDA the path forward for the regulatory approval of udenafil for the treatment of single ventricle heart disease (SVHD) in children with Fontan physiology.  More specifically, Mezzion sought clarity on the critical elements of an additional clinical trial that may be needed to complete the NDA submission. The FDA responded to the Meeting Background Packa

Abu Dhabi Stem Cells Center (ADSCC), a leading research institute in Abu Dhabi, will begin a ground-breaking clinical trial to help treat multiple sclerosis. The stem cell research hub will begin the recruitment and enrolment of 45 patients in the phase 1/2 study to evaluate the safety and efficacy of a pioneering new technology, Extracorporeal Photopheresis (ECP), which will be used in the treatment of multiple sclerosis. ADSCC's team of scientists and physicians have

AffaMed Therapeutics ("AffaMed"), a global clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products, announces that the first patient has been dosed in its US Phase 1 study of AM712 (ASKG712), a novel proprietary bispecific biologic molecule blocking both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) for the treatment of retinal diseases. The study will investigate the saf

Medical Marijuana, Inc., the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today that it has launched its first pharmaceutical subsidiary, HM Pharma, in Brazil. “We have been working hard to connect and build meaningful relationships with medical professionals and consumers in Brazil. This new sales channel will open new avenues for continu

Yingli Pharma US, Inc, a clinical stage biotechnology company developing oral small molecule drugs for cancers and other diseases with high unmet need, today announced that the first patient has been dosed in its Phase 1 clinical study evaluating YL-13027, a potent and selective TGFΒ receptor 1 (TGFΒR1) inhibitor. The dose-finding exploratory trial in patients with advanced solid tumors is being conducted in collaboration with The University of Texas MD Anderson Cancer Center and 4

InnoCare Pharma announced today that it has received approval to conduct a single-arm, open-label, multicenter phase II clinical trial evaluating the safety and efficacy of tafasitamab in combination with lenalidomide by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplantation (ASCT). Tafasitamab is a humanized Fc-mo

Microba Life Sciences Limited has signed a strategic partnership agreement (“Agreement”) with nib Holdings Limited (ASX: NHF) backed digital healthcare company Midnight Health, to deliver a personalised health service to the Australian consumer market. Under this Agreement, Midnight Health will promote, market and sell a world-first subscription-based service, known as Vidality, with its network of pharmacists to formulate personalised supplements for each customer based

Biosynth Carbosynth (“Biosynth”), a supplier of critical materials to the life science industry, announces today the acquisition of Aalto Bio Reagents (“Aalto”), a leading developer and provider of biological materials to the in-vitro diagnostic (IVD) and vaccine development industry in the field of emerging disease. The acquisition represents a further milestone in Biosynth’s development, which broadens its capabilities and offering to the IVD industry